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Parkinson's disease is a neurodegenerative disorder characterised by loss of dopaminergic
neurones in the substantia nigra pars compacta and subsequent shortage of dopamine
in the striatum of the these patients causing the well known symptoms first described by
James Parkinson in 1817. ln this thesis aspects essential to the successful application of
cellular transplantation in patients with Parkinson's disease using porcine foetal Ventral
Mesencephalic (pfVM) tissue as donor source are discussed.
Ghapter 1 is an introduction to Parkinson's disease and the various available treatment
options with a focus on cell transplantation therapy. An overview is given of the develop-
ment of cell transplantation as a therapy as well as the clinical application of cell therapy
using different cells as donor source (adrenal medulla, carotid body, human foetal mesen-
cephalon, porcine foetal mesencephalon).
Over 400 people world wide were treated in open label trials using human foetal abortion
derived tissue as donor source. The results were promising showing clinical improvement
as well as proof of principle. Two randomised double blind sham controlled trials were
conducted using human foetal aboftion derived tissue as a graft source. These studies
are subject to much crit icism concerning the techniques used as well as ethics of sham
surgery. The results oÍ these two trials were disappointing with respect to outcome and
raised alarm with respect to the severe dyskinetic side effects that were reported.
However, for patients under 60 years there was a significant clinical improvement com-
pared to placebo effect. Clinical trials using porcine foetal tissue demonstrate modest
clinical improvement and histological evidence of survival of such a xenograft in post
mortem analysis. Perhaps even more imporlantly, they show no adverse effects with
respect to the use of porcine foetal t issue as donor source.
The risks of xenotranstplantation surgery as well as infection are discussed. When using
cells from another species there is the potential risk of zoonosis, the transfer of pathogen
between species. ln theory this could endanger not only the individual receiving the
donor tissue but also the human population as a whole. The fear of such a zoonotic out-
break is currently l imiting the development of xenotransplantation therapy.
Xenotransplantation to the brain gives rise to several immunological issues that are the
result of the unique propedies of the brain as well as the use of porcine foetal mesen-
cephalic cells and are discussed.
Chapter 2 describes the efficacy of a cryopreservation protocol for pfVM cells compar-
ing cryopreserved and fresh pfVM cells. The results showed no significant differences
between the fresh and cryopreserved cells in vitro with respect to viability and number oÍ
cells per VM explant. Also, functional effect and number of surviving cells as well as graft
size did not differ after transplantation in parkinsonian rats. The conclusion was made
that the cryopreservation method used is a reliable method to store porcine foetal mesen-
cephalic cells.
The immune response against an intracerebral porcine foetal xenotransplant is largely
unknown. There is however evidence for a role of both humoral and cellular defence
mechanisms in these type of transplantations.
Humans possess xenospecific antibodies against porcine tissue and it has been shown
in vitro that human serum can lyse pfVM cells. In chapter 3 interindividual differences
were investigated in the ability to lyse pfVM cells and the levels of xenospecific antibodies,
The results show that the levels of xenospecific lgM in serum of different human subjects
terised by loss of doPaminergic
;equent shortage of doPamine
n symptoms first described bY
:o the successful aPPlication of
se using Porcine foetal Ventral
;ed.
the various available treatment
reryiew is given of the develoP-
nical application of cell theraPY
rtid body, human foetal mesen-
als using human foetal abortion
g showing clinical imProvement
ind sham controlled trials were
s a graft source. These studies
used as well as ethics of sham
rg with resPect o outcome and
Je effects that were rePorted'
:ant clinical imProvement com-
rtal tissue demonstrate modest
val of such a xenograft in Post
show no adverse effects with
ce.
:t ion are discussed. When using
,onoSis, the transfer of Pathogen
nly the individual receiving the
The fear of such a zoonotic out-
plantation theraPY.
rmunological issues that are the
re use of Porcine Íoetal mesen-
protocol for PfVM cells comPar-
rowêd no significant differences
rspect o viabil itY and number of
of surviving cells as well as graft
rats. The conclusion was made
d to store Porcine foetal mesen-
foetal xenotransPlant is largelY
h hutnoral and cellular defence
re tissue and it has been shown
lter 3 interindividual differences
levels of xenospecific antibodies'
lrum of different human subjects
varied considerable and that these levels correlated with the abil ity of these sera to lyse
pfVM cells via complement dependent cytotoxicity in vitro. These findings could be rel-
evant for patient selection for porcine transplants and chances of survival of the graft in
different patients.
Chapter 4 describes experiments designed to investigate whether PBMC display direct
or antibody dependent cytotoxicity against pfVM cells and whether priming of PBMC by
pfVM modulates pfVM directed cytotoxicity in vitro. No direct cytotoxicity of human
PBMC against pfVM could be shown, Human T-cells however are capable of kil l ing pfVM
cells, but only after they were primed by donor derived antigen presenting cells. Large
differences were found in the xenospecific T-cell response between different human indivÍduals.
The latter f inding could have implications for patient selection and chances of survival of
the graft.
In chapter 5 the effects of circulating xenospecific antibodies on early cellular responses
in vivo are described. A rat model of Parkinson's disease was used where rats possess
antibodies against pfVM cells to simulate the existence of naturally occurring antibodies
against porcine tissue in humans. The results show that graft specific antibodies in rats
bind to the grafted cells and that the cellular reaction is more outspoken and show a
trend towards a CDB response compared to non-pretreated rats.
Ghapter 6 is a general discussion in which cell transplantation in general, the use oÍ
human foetal t issue and porcine foetal t issue as well as the results of this thesis are
discussed. The place of cell transplantation as a therapy for Parkinson's disease amidst
alternative therapies and impodantly the future of cell transplantation as a therapeutic
modality in Parkinson's disease is discussed.
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